Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

2.180 -0.030 (-1.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 202,510
Open 2.240
Bid (Size) 2.160 (10)
Ask (Size) 2.240 (10)
Prev. Close 2.210
Today's Range 2.160 - 2.240
52wk Range 1.090 - 3.394
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The... 
Via FinancialNewsMedia
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+36.25%
+36.25%
1 Month
-4.80%
-4.80%
3 Month
-16.15%
-16.15%
6 Month
+81.67%
+81.67%
1 Year
+71.65%
+71.65%

More News

Read More
Oncolytics Biotech's Earnings: A Preview
Via Benzinga
5 Analysts Have This to Say About Oncolytics Biotech
Via Benzinga
Expert Ratings for Oncolytics Biotech
Via Benzinga
THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS
Via FinancialNewsMedia
Exposures Product Safety
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
Via FinancialNewsMedia
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
Via FinancialNewsMedia
Oncolytics Biotech: Q1 Earnings Insights
Via Benzinga
Pancreatic Cancer Battle Boosted by $200M VC Firm
Via FinancialNewsMedia
Topics Death
Exposures Death
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
3 Under-$20 Stocks to Buy for Explosive Returns
Via InvestorPlace
Earnings Scheduled For August 14, 2023
Via Benzinga
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Via FinancialNewsMedia
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
Via FinancialNewsMedia
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Via FinancialNewsMedia
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
Via FinancialNewsMedia
Exposures COVID-19
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
Via FinancialNewsMedia
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Via FinancialNewsMedia
Exposures Product Safety
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Via Benzinga
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.